Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02155465
Title Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

lung cancer

Therapies

Erlotinib + Ruxolitinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.